FDA Approves First Imaging Agent For Early Diagnosis Of Alzheimer’s Disease

On May 28, 2020, the U.S. Food and Drug Administration (FDA) granted marketing approval to Eli Lilly and Company for its TAUVID (flortaucipir F18) for intravenous injection. TAUVID is the first drug used to help image a distinctive characteristic of Alzheimer’s disease in the brain called tau pathology. Information regarding the roll-out of TAUVID for health care use is not available. Treatment with TAUVID is not yet covered by insurance. TAUVID is manufactured by Avid Radiopharmaceuticals, Inc., which is owned by Eli Lilly.

TAUVID is an intravenous radioactive diagnostic agent, administered by a health care professional, for . . .